^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

GSK3745417

i
Other names: GSK3745417, GSK 3745417, GSK-3745417
Associations
Trials
Company:
GSK
Drug class:
STING agonist
Associations
Trials
2ms
A Phase 1, Open Label Study of Intravenous GSK3745417 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Determine RP2D & Schedule in Participants With Relapsed or Refractory Myeloid Malignancies Including AML and HR MDS (clinicaltrials.gov)
P1, N=18, Terminated, GlaxoSmithKline | Active, not recruiting --> Terminated; The protocol was terminated on the basis of a reprioritization of organizational allocation of resources for clinical research programs.
Trial termination
|
GSK3745417
4ms
A First Time in Human (FTIH) Study of GSK3745417 Administered to Participants With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=97, Active, not recruiting, GlaxoSmithKline | Trial primary completion date: Mar 2025 --> Apr 2024
Trial primary completion date • Metastases
|
Jemperli (dostarlimab-gxly) • GSK3745417
6ms
A First Time in Human (FTIH) Study of GSK3745417 Administered to Participants With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=98, Active, not recruiting, GlaxoSmithKline | Trial completion date: Apr 2024 --> Mar 2025 | Trial primary completion date: Apr 2024 --> Mar 2025
Trial completion date • Trial primary completion date
|
Jemperli (dostarlimab-gxly) • GSK3745417
10ms
A Phase 1, Open Label Study of Intravenous GSK3745417 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Determine RP2D & Schedule in Participants With Relapsed or Refractory Myeloid Malignancies Including AML and HR MDS (clinicaltrials.gov)
P1, N=18, Active, not recruiting, GlaxoSmithKline | Recruiting --> Active, not recruiting | N=72 --> 18 | Trial completion date: Dec 2025 --> Mar 2024 | Trial primary completion date: Dec 2025 --> Mar 2024
Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
|
GSK3745417
12ms
Phase 1 First Time in Human (FTIH), Open Label Study of GSK3745417 Administered to Participants With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=98, Active, not recruiting, GlaxoSmithKline | Trial completion date: Aug 2024 --> Apr 2024
Trial completion date • Metastases
|
Jemperli (dostarlimab-gxly) • GSK3745417
over1year
Phase 1 First Time in Human (FTIH), Open Label Study of GSK3745417 Administered to Participants With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=97, Active, not recruiting, GlaxoSmithKline | Recruiting --> Active, not recruiting | N=300 --> 97 | Trial completion date: May 2025 --> Aug 2024 | Trial primary completion date: Nov 2024 --> Apr 2024
Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • Metastases
|
Jemperli (dostarlimab-gxly) • GSK3745417
over1year
P1 data
|
STING (stimulator of interferon response cGAMP interactor 1) • IFNA1 (Interferon Alpha 1) • IFNB1 (Interferon Beta 1)
|
GSK3745417
almost2years
Sting Agonist GSK3745417 Induces Apoptosis, Antiproliferation, and Cell Death in a Panel of Human AML Cell Lines and Patient Samples (ASH 2022)
GSK3745417 also blocked colony formation in primary AML samples from 5 donors.GSK3745417 is able to induce growth inhibition with transient compound incubation in vitro in as little as 30 minutes to 1 hour. Taken together, this data suggests a role for GSK3745417 as a therapeutic in AML/MDS indications through dual mechanisms of direct tumor cell killing and immune activation at a clinically relevant dose.The human biological samples were sourced ethically and their research use was in accord with the terms of the informed consents under an IRB/EC approved protocol.
Preclinical
|
STING (stimulator of interferon response cGAMP interactor 1) • IFNB1 (Interferon Beta 1)
|
GSK3745417